PUBLICATIONS

At GBT, we collaborate with academic centers to present and publish key results at medical conferences and in peer-reviewed publications. For additional information related to our data presentations and publications, please contact 1-833-GBT-4YOU (1-833-428-4968) or visit GBTMedInfo.com.

Recent Medical Meeting Presentations

62nd American Society of Hematology Annual Meeting & Exposition (2020)

Abstract
Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis

Abstract
GBT021601 Inhibits HbS Polymerization, Prevents RBC Sickling and Improves the Pathophysiology of Sickle Cell Disease in a Murine Model

Abstract
Higher Hemoglobin Levels Achieved with Voxelotor Are Associated with Lower Vaso-occlusive Crisis Incidence: 72-Week Analysis from the HOPE Study

Abstract
Improvement in the Clinical Global Impression of Change with Voxelotor in Patients with Sickle Cell Disease in the Phase 3 HOPE Trial

Abstract
Inclacumab, a Fully Human Anti-P-selectin Antibody, Directly Binds to PSGL-1 Binding Region and Demonstrates Robust and Durable Inhibition of Cell Adhesion

Abstract
Patient Perception of OxbrytaTM Treatment Benefit

Abstract
Real-World Effectiveness of Voxelotor for Treating Sickle Cell Disease in the US

Abstract
Rheological Impact of GBT1118 Cessation in a Sickle Mouse Model

Abstract
The Impact of Hemoglobin Level on Risk of End-Organ Damage among Patients with Sickle Cell Disease–A Large-Scale, Longitudinal Analysis


15th Annual Scientific Conference of Sickle Cell and Thalassaemia (2020)

Poster Presentation
Sickle Cell Anemia and COVID-19: Use of Voxelotor to Avoid Transfusion

Oral Presentation
Real-World Effectiveness of Voxelotor for the Treatment of Sickle Cell Disease: A Chart Review Study


25th European Hematology Association (EHA) Congress (2020)

Poster Presentation
Correlation Between Hemoglobin Levels and Transcranial Doppler Velocities: A Retrospective STOP 2 Analysis in Children with Sickle Cell Disease

Poster Presentation
Correlation of Voxelotor Exposure with Hemoglobin Response and Measures of Hemolysis in Patients from the HOPE Study

Poster Presentation
Concomitant Hydroxyurea and Voxelotor: Results from the HOPE Study

Poster Presentation
Incidence of Vaso-occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or After Discontinuation: Analyses of the HOPE Study



61st American Society of Hematology Annual Meeting & Exposition (2019)

Poster Presentation
Concomitant Hydroxyurea and Voxelotor: Results from the HOPE Study

Poster Presentation
Correlation of Voxelotor Exposure with Hemoglobin Response and Measures of Hemolysis in Patients from the HOPE Study

Poster Presentation
Transcranial Doppler Velocities Conversion Rate Based on Increasing Hemoglobin Concentration: Analysis from the SCCRIP Cohort Study

Poster Presentation
Chronic Kidney Disease is Under-Screened in SCD and Mild Albuminuria is Associated with a Drop in Hemoglobin: A Report from the GRNDaD Sickle Cell Registry

Poster Presentation
Incidence of Vaso-occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or After Discontinuation: Analyses of the HOPE Study

Poster Presentation
Improvement in Red Blood Cell Physiology in Children with Sickle Cell Anemia Receiving Voxelotor

Poster Presentation
Economic Burden of End Organ Damage Among Patients with Sickle Cell Disease in the US

Poster Presentation
Pharmacological Increase of Hb-O2 Affinity with a Voxelotor Analog Does Not Decrease Brain Tissue pO2 or Limit O2 Extraction in Brain Tissues of Sickle Cell Mice



24th European Hematology Association (EHA) Congress (2019)

Presidential Symposium / Oral Presentation
Results From the Randomized, Placebo-Controlled, Phase 3 Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial of Voxelotor in Adults and Adolescents With Sickle Cell Disease

Poster Presentation
Cerebral Blood Flow in Adolescents with Sickle Cell Anemia Receiving Voxelotor

Poster Presentation
Central Physiologic Mechanisms Which Augment O2 Release (Bohr Effect and 2,3-DPG Binding) Are Preserved in the Presence of Voxelotor at the Therapeutic Target of 30% Hb Modification



60th American Society of Hematology Annual Meeting & Exposition (2018)

Oral Presentation
Low Hemoglobin Increases Risk for Stroke, Kidney Disease, Elevated Pulmonary Artery Systolic Pressure, and Premature Death in Sickle Cell Disease: A Systematic Literature Review and Meta-Analysis

Oral Presentation
Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031), a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease

Oral Presentation
Interim Results From a Phase 2a Study (GBT440-007) Evaluating Adolescents With Sickle Cell Disease Treated with Multiple Doses of Voxelotor (GBT440)

Poster Presentation
Societal Costs of Sickle Cell Disease in the United States